- Home
- RC vs PSNL Comparison
RC vs PSNL Comparison
Compare RC & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RC
- PSNL
- Stock Information
- Founded
- RC 2007
- PSNL 2011
- Country
- RC United States
- PSNL United States
- Employees
- RC N/A
- PSNL N/A
- Industry
- RC Real Estate Investment Trusts
- PSNL Medical Specialities
- Sector
- RC Real Estate
- PSNL Health Care
- Exchange
- RC Nasdaq
- PSNL Nasdaq
- Market Cap
- RC 517.6M
- PSNL 518.8M
- IPO Year
- RC N/A
- PSNL 2019
- Fundamental
- Price
- RC $3.05
- PSNL $9.55
- Analyst Decision
- RC Hold
- PSNL Strong Buy
- Analyst Count
- RC 5
- PSNL 5
- Target Price
- RC $6.10
- PSNL $8.70
- AVG Volume (30 Days)
- RC 2.3M
- PSNL 1.3M
- Earning Date
- RC 11-07-2025
- PSNL 11-04-2025
- Dividend Yield
- RC 16.39%
- PSNL N/A
- EPS Growth
- RC N/A
- PSNL N/A
- EPS
- RC N/A
- PSNL N/A
- Revenue
- RC N/A
- PSNL $80,317,000.00
- Revenue This Year
- RC N/A
- PSNL N/A
- Revenue Next Year
- RC $141.93
- PSNL $29.83
- P/E Ratio
- RC N/A
- PSNL N/A
- Revenue Growth
- RC N/A
- PSNL 0.36
- 52 Week Low
- RC $3.02
- PSNL $2.83
- 52 Week High
- RC $7.64
- PSNL $10.95
- Technical
- Relative Strength Index (RSI)
- RC 25.78
- PSNL 62.18
- Support Level
- RC $3.05
- PSNL $9.40
- Resistance Level
- RC $3.22
- PSNL $9.93
- Average True Range (ATR)
- RC 0.10
- PSNL 0.89
- MACD
- RC -0.00
- PSNL -0.03
- Stochastic Oscillator
- RC 6.00
- PSNL 55.84
About RC Ready Capital Corproation
Ready Capital Corp is a real estate finance company. It acquires, manages, originates, and finances small-balance commercial loans to purchase small multi-family, office, retail, mixed-use, or warehouse properties. The company's segments consist of LMM Commercial Real Estate and Small Business Lending. It generates the majority of its revenue from LMM Commercial Real Estate.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.